Literature DB >> 14685841

Troponin I levels in a hemolytic uremic syndrome patient with severe cardiac failure.

Varvara Askiti1, Kristine Hendrickson, Alfred J Fish, Elizabeth Braunlin, Alan R Sinaiko.   

Abstract

Troponins are highly sensitive and specific biochemical markers of myocardial injury that are released into the circulation during myocardial ischemia. We describe changes in cardiac troponin I (cTnI) prior to and following clinical evidence of severe myocardial dysfunction in a child with hemolytic uremic syndrome (HUS). A previously healthy, 22-month-old girl presented with typical HUS and stool cultures positive for Escherichia coli O157:H7. She required dialysis, blood and platelet transfusions, and insulin for HUS-related diabetes mellitus. On the 6th hospital day she had sudden circulatory collapse with a blood pressure of 70/40 mmHg and an oxygen saturation of 88%. She responded rapidly to emergency resuscitation but had diminished left ventricular function (ejection fraction 18%). Four days after the acute event an echocardiogram showed normal ventricular size and contractility. She underwent hemodialysis for 22 days, and renal function was normal after 33 days. cTnI levels were measured with a microparticle enzyme immunoassay. cTnI was normal (>0.4 microg/l) 32 h prior to cardiac collapse, mildly increased (2.1 microg/l) 8 h before the cardiac collapse, severely elevated shortly after the cardiac event (43.1 microg/l), and peaked (140.6 microg/l) at 24 h. It then fell gradually and was normal at discharge. These results suggest that measurement of cTnI may be a useful predictor of cardiac involvement in severely affected children with HUS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14685841     DOI: 10.1007/s00467-003-1343-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  24 in total

1.  Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes.

Authors:  Y Sato; T Yamada; R Taniguchi; K Nagai; T Makiyama; H Okada; K Kataoka; H Ito; A Matsumori; S Sasayama; Y Takatsu
Journal:  Circulation       Date:  2001-01-23       Impact factor: 29.690

2.  Specificity of cardiac troponins I and T in renal disease.

Authors:  S Willging; F Keller; G Steinbach
Journal:  Clin Chem Lab Med       Date:  1998-02       Impact factor: 3.694

3.  Haemolytic-uraemic syndrome: clinical experience of an outbreak in the West Midlands.

Authors:  C M Taylor; R H White; M H Winterborn; B Rowe
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-07

Review 4.  Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome.

Authors:  R L Siegler
Journal:  J Pediatr       Date:  1994-10       Impact factor: 4.406

5.  Elevation of serum cardiac troponin I in noncardiac and cardiac diseases other than acute coronary syndromes.

Authors:  I A Khan; A Tun; N Wattanasauwan; M T Win; T A Hla; A Hussain; B C Vasavada; T J Sacchi
Journal:  Am J Emerg Med       Date:  1999-05       Impact factor: 2.469

6.  A clinicopathological study of 24 children with hemolytic uremic syndrome. A report of the Southwest Pediatric Nephrology Study Group.

Authors:  J C Argyle; R J Hogg; T J Pysher; F G Silva; R L Siegler
Journal:  Pediatr Nephrol       Date:  1990-01       Impact factor: 3.714

7.  Cardiac troponin T in patients with clinically suspected myocarditis.

Authors:  B Lauer; C Niederau; U Kühl; M Schannwell; M Pauschinger; B E Strauer; H P Schultheiss
Journal:  J Am Coll Cardiol       Date:  1997-11-01       Impact factor: 24.094

Review 8.  Causes of death in hemolytic uremic syndrome.

Authors:  W L Robson; A K Leung; M D Montgomery
Journal:  Child Nephrol Urol       Date:  1991

9.  Myocarditis and haemolytic uraemic syndrome.

Authors:  I Abu-Arafeh; E Gray; G Youngson; I Auchterlonie; G Russell
Journal:  Arch Dis Child       Date:  1995-01       Impact factor: 3.791

Review 10.  Extrarenal involvement in diarrhoea-associated haemolytic-uraemic syndrome.

Authors:  E G Gallo; C A Gianantonio
Journal:  Pediatr Nephrol       Date:  1995-02       Impact factor: 3.714

View more
  9 in total

1.  Azithromycin decolonization of STEC--a new risk emerges.

Authors:  Michael E Seifert; Phillip I Tarr
Journal:  Nat Rev Nephrol       Date:  2012-06-05       Impact factor: 28.314

Review 2.  Guidelines for the management and investigation of hemolytic uremic syndrome.

Authors:  Takashi Igarashi; Shuichi Ito; Mayumi Sako; Akihiko Saitoh; Hiroshi Hataya; Masashi Mizuguchi; Tsuneo Morishima; Kenji Ohnishi; Naohisa Kawamura; Hirotsugu Kitayama; Akira Ashida; Shinya Kaname; Hiromichi Taneichi; Julian Tang; Makoto Ohnishi
Journal:  Clin Exp Nephrol       Date:  2014-08       Impact factor: 2.801

Review 3.  Long-term outcomes of Shiga toxin hemolytic uremic syndrome.

Authors:  Joann M Spinale; Rebecca L Ruebner; Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2013-01-04       Impact factor: 3.714

Review 4.  Direct cardiac involvement in childhood hemolytic-uremic syndrome: case report and review of the literature.

Authors:  Davide Rigamonti; Giacomo D Simonetti
Journal:  Eur J Pediatr       Date:  2016-09-23       Impact factor: 3.183

Review 5.  Hemolytic uremic syndrome.

Authors:  Nur Canpolat
Journal:  Turk Pediatri Ars       Date:  2015-06-01

6.  Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS).

Authors:  Myda Khalid; Sharon Andreoli
Journal:  Pediatr Nephrol       Date:  2018-11-01       Impact factor: 3.714

7.  HUS-induced cardiac and circulatory failure is reversible using cardiopulmonary bypass as rescue.

Authors:  René F Andersen; Jesper V Bjerre; Johan V Povlsen; Mette Veien; Konstantinos Kamperis; Søren Rittig
Journal:  Pediatr Nephrol       Date:  2017-08-05       Impact factor: 3.714

Review 8.  Extra-renal manifestations of complement-mediated thrombotic microangiopathies.

Authors:  Johannes Hofer; Alejandra Rosales; Caroline Fischer; Thomas Giner
Journal:  Front Pediatr       Date:  2014-09-08       Impact factor: 3.418

Review 9.  Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS).

Authors:  Johanna Scheiring; Sharon P Andreoli; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-08-13       Impact factor: 3.714

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.